CADA, a potential anti-HIV microbicide that specifically targets the cellular CD4 receptor

Current HIV Research

Volumn 6, Issue 3, 2008, Pages 246-256

  Vermeire, Kurt ^a   Brouwers, Joachim ^b   Van Herrewege, Yven ^c   Le Grand, Roger ^d   Vanham, Guido ^c,e   Augustijns, Patrick ^b   Bell, Thomas W ^f   Schols, Dominique ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^c INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^d INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^e UNIVERSITY OF ANTWERP   (Belgium)

^f UNIVERSITY OF NEVADA   (United States)

Author keywords

Broad spectrum; CD4 receptor; Cyclotriazadisulfonamide (CADA); HIV entry; Microbicide; SIV

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 ANTIGEN; CELLACEFATE; CYCLOTRIAZADISULFONAMIDE; LYMPHOCYTE ANTIGEN RECEPTOR; MICROBICIDE;

ANIMAL CELL; ANTIVIRAL ACTIVITY; CD4+ T LYMPHOCYTE; CELL SURFACE; COCULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DENDRITIC CELL; DOWN REGULATION; DRUG FORMULATION; DRUG MECHANISM; DRUG SYNTHESIS; FEASIBILITY STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; MACACA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS INFECTION; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; ANTI-HIV AGENTS; ANTIGENS, CD4; CELLULOSE; CYTOPATHOGENIC EFFECT, VIRAL; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FLOW CYTOMETRY; HETEROCYCLIC COMPOUNDS; HIV; HIV INFECTIONS; HUMANS; MACACA FASCICULARIS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES; VIRUS INTERNALIZATION;

EID: 47749110946     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016208784324958     Document Type: Review

References (61)

1. Klasse PJ, Shattock R, Moore JP. Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annu Rev Med 2008; 59: 291-307.
2. Quinn TC, Overbaugh J. HIV/AIDS in women: an expanding epidemic. Science 2005; 308: 1582-1583.
3. Balzarini J, Van Damme L. Microbicide drug candidates to prevent HIV infection. Lancet 2007; 369: 787-797.
4. Bones S, Mccormack WM. Inhibition of growth of Chlamydia trachomatis by nonoxynol-9 in vitro. Antimicrob Agents Chemother 1985; 27: 724-726.
5. Bourinbaiar AS, Fruhstorfer EC. The efficacy of nonoxynol-9 from an in vitro point of view. AIDS 1996; 10: 558-559.
6. Hicks DR, Martin LS, Getchell JP, et al. Inactivation of HTLV-III lav-infected cultures of normal human-lymphocytes by nonoxynol-9 in vitro. Lancet 1985; 2: 1422-1423.
7. Kelly JP, Reynolds RB, Stagno S, Louv WC, Alexander WJ. In vitro activity of the spermicide nonoxynol-9 against Chlamydia trachomatis. Antimicrob Agents Chemother 1985; 27: 760-762.
8. Miller CJ, Kang DW, Marthas M, et al. Genital secretory immune-response to chronic simian immunodeficiency virus (SIV) infection: a comparison between intravenously and genitally inoculated rhesus macaques. Clin Exp Immunol 1992; 88: 520-526.
9. Polsky B, Baron PA, Gold JWM, Smith JL, Jensen RH, Armstrong D. In vitro inactivation of HIV-1 by contraceptive sponge containing nonoxynol-9. Lancet 1988; 1: 1456.
10. Van Damme L, Ramjee G, Alary M, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 2002; 360: 971-977.
11. Schwartz JI, Mauck C, Lai JJ, et al. Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind Phase I safety study. Contraception 2006; 74: 133-140.
12. Whitehead SJ, Kilmarx PH, Blanchard Y, et al. Acceptability of Carraguard vaginal gel use among Thai couples. AIDS 2006; 20: 2141-2148.
13. Keller MJ, Guzman E, Hazrati E, et al. PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity. AIDS 2007; 21: 467-476.
14. Vermeire K, Zhang Y, Princen Y, et al. CADA inhibits human immunodeficiency virus and human berpesvirus 7 replication by down-modulation of the cellular CD4 receptor. Virology 2002; 302: 342-353.
15. Vermeire K, Princen K, Hatse S, et al. CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro. AIDS 2004; 18: 2115-2125.
16. Lisco A, Grivel JC, Biancotto A, et al. Viral interactions in human lymphaid tissue: human herpesvirus 7 suppresses the replication of CCR5-tropic human immunodeficiency virus type 1 via CD4 modulation. J Virol 2007; 81: 708-7117.
17. Vermeire K, Bell TW, Choi HJ, et al. The anti-HIV potency of cyclotriazadisulfonamide analogs is directly correlated with their ability to down-modulate the CD4 receptor. Mol Pharmacol 2003; 63: 203-210.
18. Verineire K, Lisco A. Grivel JC, et al. Design and cellular kinetics of dansyl-labeled CADA derivatives with anti-HIV and CD4 receptor down-modulating activity. Biochem Pharmacol 2007; 74: 566-578.
19. Bell TW, Anugu S, Bailey P, et al. Synthesis and structure-activity relationship studies of CD4 down-modulating cyclotriazadisulfonamide (CADA) analogues. J Med Chem 2006; 49: 1291-1312.
20. Benlhassan-Chahour K, Penit C, Dioszeghy V, et al. Kinetics of lymphocyte proliferation during primary immune response in macaques infected with pathogenic simian immunodeficiency virus SIVmac251: preliminary report of the effect of early antiviral therapy. J Virol 2003; 77: 12479-12493.
21. Gay W, Lauret E, Boson B, et al. Low autocrine interferon beta production as a gene therapy approach for AIDS: Infusion of interferon beta-engineerrd lymphocytes in macaques chronically infected with SIVmac251. Retrovirology 2004; 1: 29.
22. Egberink HF, De Clereq E, Van Vliet AL, et al. Bicyclams, selective antagonists of the human chemokine receptor CXCR4, potently inhibit feline immunodeficiency virus replication. J Virol 1999; 73: 6346-6352.
23. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs of enzyme inhibitors. Adv Enzyme Regul 1994; 22: 27-55.
24. Shimojima M, Miyazawa T, Ikeda Y, et al. Use of CD134 as a primary receptor by the feline immunodeficiency virus. Science 2004; 303: 1192-1195.
25. Rusconi S, Scozzafava A, Mastrolorenzo A, Supuran CF. An update in the development of HIV entry inhibitors. Curr Top Med Chem 2007; 7: lZ73-1289.
26. Vermeire K, Schols D, Bell TW. Inhibitors of HIV infection via the cellular CD4 receptor. Curr Mod Chem 2006; 13: 731-743.
27. Vermeire K, Schols D. Specific CD4 down-modulating compounds with potent anti-HIV activity. J Leukoc Biol 2003; 74: 667-675.
28. Pope M, Haase AT. Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat Med 2003; 9: 847-852.
29. Turville SG, Santos A Frank I, et al. Immunodeficiency virus uptake, turnover, and 2-phase transfer in human dendritic cells. Blood 2004; 103: 2170-2179.
30. Turville SG, Vermeire K, Balzarini J, Schols D. Sugar-binding proteins potently inhibit dondritic cell human immunodeficiency virus type 1 (HIV-1) infection and dendritic-cell-directed HIV-1 transfer. J Virol 2005; 79: 13519-13527.
31. Burleigh L, Lozach PY, Schiffer C, et al. Infection of dendritic. cells (DCs), not DC-SIGN-mediated internalization of human immunodeficiency virus, is required for long-term transfer of virus munodeficiency virus, is required for long-term transfer of virus to T cells. J Virol 2006; 80: 2949-2957.
32. Hu Q, Frank I, Williams V, et al. Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue. J Exp Med 2004; 199: 1065-1075.
33. Mokili J, Korber B. The spread of HIV in Africa. J Neurovirol 2005; 11(Suppl. 1): 66-75.
34. Binley JM, Wrin T, Korber B, et al. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 2004; 78: 13232-13252.
35. Lin PF, Blair W, Wang T, et al. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci USA 2003; 100: 11013-11018.
36. Brown BK, Darden JM, Tovanabutra S, et al. Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01Æ, and CRFO2_AG, for the development and assessment of candidate vaccines. J Virol 2005; 79: 6089-6101.
37. Blish CA, Nedellec R, Mandaliya K, Mosier DE, Overbaugh J. HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry. AIDS 2007; 21: 693-702.
38. Li M, Gao F, Mascola JR, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005; 79: 10108-10125.
39. Li M, Salazar-Gonzalez JF, Derdeyn CA, et al. Genetic and neutratization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol 2006; 80: 11776-11790.
40. Choudbry V, Zhang MY, Harris I, et al. Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration. Biochem Biophys Res Commun 2006; 348: 1107-1115.
41. Li Y, Migueles SA, Welcher B, et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 2007; 13: 1032-1034.
42. Huskens D, Van Laethem K, Vermeire K, Balzarini J, Schols D. Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12. Virology 2007; 360: 294-304.
43. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 1998; 72: 2855-2864.
44. Kozak SL, Platt EJ, Madani N, Ferro FE, Jr., Peden Y, Kabat D. CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1. J Virol 1997; 71: 873-882.
45. Platt EJ, Madani N, Kozak SL, Kabat D. Infectious properties of human immunodeficiency virus type 1 mutants with distinct affinities for the CD4 receptor. J Virol 1997; 71: 883-890.
46. Veazey RS, Klasse PJ, Schader SM, et al. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 2005; 439: 99-102.
47. Veazey, RS, Springer MS, Marx PA, Dufour J, Klasse PJ, Moore JP. Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat Med 2005; 11: 1293-1294.
48. Veazey RS, Klasse PJ, Ketas TJ, et al. Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J Exp Med 2003; 198: 1551-1562.
49. Lederman NK Veazey RS, Offord R, et al. Prevention of vaginal SHIV transmission in thesus macaques through inhibition of CCR5. Science 2004; 306: 485-487.
50. Veazey RS, Shattock RJ, Pope M, et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 2003; 9: 343-346.
51. Tien D, Schnaare RI, Kang F, et al. In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res Hum RetYoviruses 2005; 21: 845-853.
52. Brewster ME, Leftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev 2007; 59: 645-666.
53. Francois M, Snoeckx F, Putteman P, et al. A mucoadhesive, cyclodextrin-based vaginal cream formulation of itraconazole. AAPS J 2003; 5: E5.
54. Graham DR, Chertova E, Hilburn JM, Arthur LO, Hildreth JE. Cholesterol depletion of human immunodeficiency virus type 1 and sinuan immunodeficiency virus with beta-cyclodextrin inactivates and permeabilizes the virions: evidence for virion-associated lipid rafts. J Virol 2003; 77: 8237-8248.
55. Popik W, Alce TM, An WC. Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4(+) T cells. J Virol 2002; 76: 4709-4722.
56. Ketas TJ, Schader SM, Zurita J, et al. Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes. Virology 2007; 364: 431-440.
57. Neurath AR, Strick N, Li YY, Debriath AK. Cellulose acetate phthalate, a common pharmaceutical excipient, inactivates HIV-1 and blocks the coreceptor binding site on the virus envelope glycoprotein gp120. BMC Infect Dis 2001; 1: 17.
58. Neurath AR, Strick N, Jiang S, Li YY, Deboath AK. Anti-HIV-1 activity of cellulose acetate phthalate: synergy with soluble CD4 and induction of "dead-end" gp41 six-helix bundles. BMC Infect Dis 2002; 2: 6.
59. Cummins JE, Jr., Guarner J, Flowers L, et al. Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture. Antimicrob Agents Clemother 2007; 51: 1770-1779.
60. Liu S, Lu H, Neurath AR, Jiang S. Combination of candidate microbicides cellulose acetate 1,2-benzenedicarboxylate and UC781 has synergistic and complementary effects against human immunodeficiency virus type 1 infection. Antimicrob Agents Chemother 2005; 49: 1830-1836.
61. Ratterree M, Gettie A. Williams V, et al. Safety and distribution of cellulose acetate 1,2-benzenedicarboxylate (CAP), a candidate anti-HIV microbicide in rhesus macisques. AIDS 2005; 19: 1595-1599.